Physician profile
James E Burrow
NPI 1659819688
$801.14
in general payments reported to CMS, 2019-2025
14 companies · $571 in 2025
The $571 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $43.88 · 2024: $187 · 2025: $571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $801.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $180.88 | 2024-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $137.81 | 2025 | Farxiga, Airsupra, Breztri |
| Exact Sciences Corporation | $93.71 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.41 | 2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $65.02 | 2024-2025 | Caplyta |
| Verona Pharma, INC. | $63.17 | 2025 | Ohtuvayre |
| Organogenesis INC. | $33.86 | 2024 | |
| Kerecis Limited | $29.81 | 2023-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Bioventus LLC | $24.38 | 2023 | |
| Sumitomo Pharma America, INC. | $24.23 | 2025 | Gemtesa |
| Pfizer INC. | $21.00 | 2025 | |
| Phathom Pharmaceuticals, INC. | $20.63 | 2025 | Voquezna |
| Lilly USA, LLC | $17.46 | 2025 | Mounjaro |
| Glaxosmithkline, LLC. | $13.77 | 2025 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Burrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.